CompanyGraph
Sihuan Pharmaceutical Holdings Group Ltd.
0460 · HKEX · Hong Kong
Price data from its TEL1 listing on XSTU, quoted in EUR
sihuanpharm.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.58B, above the global median of $1.15B
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.20%Below 5Y avg (2.57%)
Annual Rate
HKD 0.01Paid annual
Payout Ratio
50.6%Sustainable
Payback Period
8.2 yr
Last Ex-Dividend
Jun 30, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
12.36BHKD1.58B · vs all stocks (USD)
Trailing P/E
42.50xRevenue (TTM)
3.05BHKD388.48M · vs all stocks (USD)
Profit Margin
6.86%Beta
0.8940xvs all stocks
52-Week Change
-38.44%vs all stocks
Market Capitalization
12.36BHKD1.58B · vs all stocks (USD)
Enterprise Value
6.72BHKD857.08M · vs all stocks (USD)
Trailing P/E
42.50xForward P/E
-42.50xPrice to Sales (TTM)
2.93xPrice to Book (MRQ)
1.13xEnterprise to Revenue
2.21xEnterprise to EBITDA
8.99xProfit Margin
6.86%Operating Margin
18.39%Return on Assets (TTM)
2.69%Return on Equity (TTM)
3.13%Revenue (TTM)
3.05BHKD388.48M · vs all stocks (USD)
Revenue per Share (TTM)
0.2870HKDUpdated Aug 20, 2026Quarterly Revenue Growth
54.70%Gross Profit (TTM)
2.10BHKD267.38M · vs all stocks (USD)
EBITDA (TTM)
795.39MHKD101.44M · vs all stocks (USD)
Net Income (TTM)
209.07MHKD26.66M · vs all stocks (USD)
Operating Cash Flow (TTM)
-27.41MHKD-3.50M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-229.42MHKD-29.26M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0109HKDUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.20%vs all stocks
5-Year Average Dividend Yield
2.57%vs all stocks
Payout Ratio
50.61%Minority Interest (Equity)
1.05BCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0197CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0197CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
9.12BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
9.12BSharesFY2025 · Dec 31, 2025Operating Cash Flow
-366.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-383.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.56BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
417.16MCNYFY2025 · Dec 31, 2025Stock-based Compensation
9.03MCNYFY2025 · Dec 31, 2025Other Non-cash Items
102.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-690.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-204.72MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.05MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-136.15MCNYFY2025 · Dec 31, 2025Net Acquisitions
31.68MCNYFY2025 · Dec 31, 2025Purchase of Investments
-8.20BCNYFY2025 · Dec 31, 2025Sale of Investments
7.81BCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.15MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-395.44MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
272.41MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-277.95MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-188.63MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-90.89MCNYFY2025 · Dec 31, 2025Other Financing Charges
706.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
421.65MCNYFY2025 · Dec 31, 2025Shares Outstanding
9.04BSharesUpdated Aug 20, 2026Float Shares
3.70BSharesUpdated Aug 20, 2026% Held by Insiders
56.25%vs all stocks
% Held by Institutions
6.84%vs all stocks
Total Cash (MRQ)
4.63BHKD590.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4400HKDUpdated Aug 20, 2026Total Debt (MRQ)
1.13BHKD144.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1408xCurrent Ratio (MRQ)
1.80xBook Value per Share (MRQ)
0.7529HKDUpdated Aug 20, 2026Total Assets
11.63BCNY1.73B · vs all stocks (USD)
Total Current Assets
6.65BCNYFY2025 · Dec 31, 2025Total Liabilities
4.73BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.98BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.69BCNYFY2025 · Dec 31, 2025Cash
3.05BCNYFY2025 · Dec 31, 2025Cash Equivalents
511.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.56BCNYFY2025 · Dec 31, 2025Other Short-term Investments
416.78MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025Inventory
617.73MCNYFY2025 · Dec 31, 2025Accounts Payable
387.72MCNYFY2025 · Dec 31, 2025Short-term Debt
272.09MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.29BCNYFY2025 · Dec 31, 2025Long-term Debt
734.58MCNYFY2025 · Dec 31, 2025Common Stock (Book)
77.06MCNYFY2025 · Dec 31, 2025Retained Earnings
601.75MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.90BCNY1.02B · vs all stocks (USD)
Treasury Stock
242.73MCNYFY2025 · Dec 31, 202552-Week Low
0.8200HKDUpdated Aug 20, 202652-Week High
1.92HKDUpdated Aug 20, 202652-Week Change
-38.44%vs all stocks
Beta
0.8940xvs all stocks
50-Day MA
0.8874HKDUpdated Aug 20, 2026200-Day MA
1.24HKDUpdated Aug 20, 2026Avg 10-Day Volume
22.12MSharesUpdated Aug 20, 2026Avg 30-Day Volume
29.45MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.0200HKDUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 26,664,903.224Operating Cash Flow (USD, TTM): -3,496,192.291
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.58B, above the global median of $1.15BNotable
Market cap (USD): 1,576,124,535.436Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule